# Lisata Therapeutics, Inc. (LSTA)

> Source: Nexqual · https://nexqual.com/LSTA · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Lisata Therapeutics, Inc. (LSTA), nexqual.com/LSTA" · informational, not investment advice.

**Price:** USD 1.07 (+4.90% on the day) · last close of Oct 15, 2026; US market pre market, not a live price. Prev close 1.02 · day 1–1.07 · 52w 0.98–5.07 · market cap $11.6M · NCM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $100K, net income -$14.6M (-14621.0% margin), free cash flow -$12.3M (SEC filings).
- Analysts: Hold (mean 3.00 on a 1–5 scale) (2 analysts).
- Total return with dividends: 1Y -57.5% vs S&P 500 +18.1%; 5Y -94.2% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD —, revenue estimate $0K.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2023 | FY2023 | FY2024 | FY2024 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | $0K | $0K | $1.0M | $170K | $100K |
| Operating income | -$29.1M | -$57.6M | -$25.7M | -$22.4M | -$18.2M | -$16.4M |
| Net income | -$27.5M | -$54.2M | -$20.8M | -$20.0M | -$16.6M | -$14.6M |
| EPS (diluted) | -$7.45 | -$10.47 | -$2.58 | -$2.40 | -$1.91 | — |
| Free cash flow | -$22.3M | -$21.5M | -$20.0M | -$19.4M | -$16.0M | -$12.3M |
| Operating margin | — | — | — | -2240.9% | -10711.2% | -16427.0% |
| Net margin | — | — | — | -1998.5% | -9756.5% | -14621.0% |
| Revenue growth | — | — | — | — | -83.0% | — |
| Cash + short-term investments | $91.5M | $64.7M | $44.7M | $25.6M | $16.0M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 115.6x · P/B 1.4x · FCF yield -106.60% · Earnings yield -126.48%

## Analysts
Consensus Hold (mean 3.00 on a 1–5 scale), 2 analysts.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -57.5% | -94.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -57.7% | -43.3% |
| Volatility (annualized) | 117.7% | 81.3% |
| Max drawdown | -80.4% (Mar 2026→Jul 2026) | -94.6% (Oct 2021→Jul 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/LSTA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt